Literature DB >> 7507927

The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor.

D Seiffert1, G Ciambrone, N V Wagner, B R Binder, D J Loskutoff.   

Abstract

We recently localized the high affinity binding site for activated type 1 plasminogen activator inhibitor (PAI-1) to the somatomedin B domain (i.e. amino acid (aa) 1-51) of vitronectin (Vn). In this study to further define this site, N-terminal Vn fragments of various lengths were expressed in Escherichia coli and tested for PAI-1 binding activity. Vn polypeptides containing aa 1-52 and 1-40 retained PAI-1 binding activity and stabilized PAI-1 to a similar extent as intact Vn, but polypeptides containing aa 1-30 did not bind to PAI-1 nor stabilize its activity. The effects of monoclonal antibodies (mAbs) to Vn on PAI-1 binding was also determined. One mAb bound to Vn and blocked its ability to bind to PAI-1. It also dissociated pre-existing PAI-1.Vn complexes, and prevented the incorporation of PAI-1 into extracellular matrix of HT 1080 cells. This mAb bound to the recombinant peptide containing aa 1-40, but not to the peptide consisting of aa 1-30. A second randomly chosen mAb with similar affinity for Vn was inactive in these assays and bound to the region between aa 52 and 239. These results indicate that the high affinity binding site for active PAI-1 in Vn is between aa 1 and 40, and that this domain may also stabilize active PAI-1.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7507927

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

1.  Thrombospondin-1 and transforming growth factor beta-1 upregulate plasminogen activator inhibitor type 1 in pancreatic cancer.

Authors:  D Albo; D H Berger; J Vogel; G P Tuszynski
Journal:  J Gastrointest Surg       Date:  1999 Jul-Aug       Impact factor: 3.452

2.  Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin.

Authors:  D A Waltz; L R Natkin; R M Fujita; Y Wei; H A Chapman
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

3.  Amphibian DNases I are characterized by a C-terminal end with a unique, cysteine-rich stretch and by the insertion of a serine residue into the Ca2+-binding site.

Authors:  H Takeshita; T Yasuda; R Iida; T Nakajima; S Mori; K Mogi; Y Kaneko; K Kishi
Journal:  Biochem J       Date:  2001-07-15       Impact factor: 3.857

4.  Solution structure of recombinant somatomedin B domain from vitronectin produced in Pichia pastoris.

Authors:  Magnus Kjaergaard; Henrik Gårdsvoll; Daniel Hirschberg; Steen Nielbo; Anand Mayasundari; Cynthia B Peterson; Anna Jansson; Thomas J D Jørgensen; Flemming M Poulsen; Michael Ploug
Journal:  Protein Sci       Date:  2007-09       Impact factor: 6.725

5.  Molecular framework for angiogenesis: a complex web of interactions between extravasated plasma proteins and endothelial cell proteins induced by angiogenic cytokines.

Authors:  D R Senger
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

6.  Plasminogen Activator Inhibitor-1 Promotes the Recruitment and Polarization of Macrophages in Cancer.

Authors:  Marta Helena Kubala; Vasu Punj; Veronica Rae Placencio-Hickok; Hua Fang; G Esteban Fernandez; Richard Sposto; Yves Albert DeClerck
Journal:  Cell Rep       Date:  2018-11-20       Impact factor: 9.423

7.  Opposing effects of collagen I and vitronectin on fibronectin fibril structure and function.

Authors:  Candace D Gildner; Daniel C Roy; Christopher S Farrar; Denise C Hocking
Journal:  Matrix Biol       Date:  2014-02-06       Impact factor: 11.583

8.  Provisional Matrix Deposition in Hemostasis and Venous Insufficiency: Tissue Preconditioning for Nonhealing Venous Ulcers.

Authors:  Tony J Parker; James A Broadbent; Jacqui A McGovern; Daniel A Broszczak; Christina N Parker; Zee Upton
Journal:  Adv Wound Care (New Rochelle)       Date:  2015-03-01       Impact factor: 4.730

9.  Cyr61/CCN1 displays high-affinity binding to the somatomedin B(1-44) domain of vitronectin.

Authors:  Ivo M B Francischetti; Michalis Kotsyfakis; John F Andersen; Jan Lukszo
Journal:  PLoS One       Date:  2010-02-26       Impact factor: 3.240

10.  Antimetastatic potential of PAI-1-specific RNA aptamers.

Authors:  Charlene M Blake; Bruce A Sullenger; Daniel A Lawrence; Yolanda M Fortenberry
Journal:  Oligonucleotides       Date:  2009-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.